Abstracts Archive - Page 1472 of 2425 - ACR Meeting Abstracts

Abstract Number: 814 • 2016 ACR/ARHP Annual Meeting
The Regulatory B Cells Ameliorate Skin Sclerosis, Lung Fibrosis, and Autoimmunity Via an Anti-Oxidative Effect in Systemic Sclerosis Model Mice
Ayumi Yoshizaki, Takemichi Fukasawa, Satoshi Ebata, Kouki Nakamura, Takashi Yamashita, Ryosuke Saigusa, Yohei Ichimura, Takehiro Takahashi, Takashi Taniguchi, Asano Yoshihide and Shinichi Sato, Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease characterized by vascular damage, excessive deposition of extracellular matrix, and fibrosis in the several organs, including…
Abstract Number: 815 • 2016 ACR/ARHP Annual Meeting
The Novel Anti-BICD2 Autoantibody Potentially Predicts a Favorable Disease Course in SSc
Johannes Schulte-Pelkum¹, Daniel Wirtz¹, Petra Budde¹, Hans-Dieter Zucht¹, Peter Schulz-Knappe¹, Prof. Dr. Matthias Schneider², Suzana Jordan³, Oliver Distler³, Britta Maurer³ and Nicolas Hunzelmann⁴, ¹Protagen AG, Dortmund, Germany, ²Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany, ³Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Department of Dermatology, University of Cologne, Cologne, Germany
Background/Purpose: To evaluate clinical associations of our recently discovered systemic sclerosis-specific auto-antigen BICD2 in clinically well characterized systemic sclerosis (SSc) cohorts from two tertiary referral…
Abstract Number: 816 • 2016 ACR/ARHP Annual Meeting
Clinical Response to Treatment with Belimumab and Mycophenolate Mofetil Is Associated with Decrease in B Cell, TGF-β and PDGF Signaling in Systemic Sclerosis
Viktor Martyanov¹, Jessica K. Gordon², Tammara A. Wood¹, Robert F. Spiera² and Michael L. Whitfield¹, ¹Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: While B cell signaling is thought to be important in the pathogenesis of systemic sclerosis (SSc), the experience with B cell targeting therapies in…
Abstract Number: 817 • 2016 ACR/ARHP Annual Meeting
RNA and Protein Cargo of Exosomes Isolated from Serum of Systemic Sclerosis Patients Induce a Profibrotic Phenotype in Cultured Normal Human Dermal Fibroblasts: A Potential Mechanism for the Initiation and Progression of a Profibrotic Phenotype in SSc
Peter J. Wermuth, Kellan R. Carney, Sonsoles Piera-Velazquez and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Exosomes are lipid bilayer-bound microvesicles that contain various macromolecules including numerous microRNA (miRNA) and proteins. Exosomes mediate intercellular communication by fusing and releasing their…
Abstract Number: 818 • 2016 ACR/ARHP Annual Meeting
The Role of Endothelin 1 in Activation of Vascular Smooth Muscle Cells in Systemic Sclerosis; Increased Cell Proliferation and Resistance to Apoptosis Mediated By Endotehlin B Receptors
Shadia Nada¹, Yongqing Wang^1,2, Nezam Altorok¹ and Bashar Kahaleh¹, ¹Medicine/Rheumatology, University of Toledo, Toledo, OH, ²Medicine, University of Toledo, Toledo, OH
Background/Purpose: is overexpressed in SSc as illustrated by elevated circulating levels and increased tissue expression in involved organs. We previously reported vascular smooth muscle…
Abstract Number: 819 • 2016 ACR/ARHP Annual Meeting
Impaired Adiponectin Signaling in SSc Contributes to Myofibroblast Differentiation and Organ Fibrosis
Roberta Goncalves Marangoni¹, Benjamin Korman², Feng Fang¹, Monique Hinchcliff¹, Laszlo Otvos³, Philipp E. Scherer⁴, Warren Tourtellotte⁵ and John Varga⁶, ¹Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ²Department of Rheumatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ³Temple University, Philadelphia, PA, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵Department of Pathology, Ward, Northwestern University, Chicago, IL, ⁶Rheumatology and Dermatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL
Background/Purpose: In systemic sclerosis (SSc) patients, skin fibrosis is accompanied by involution of dermal white adipose tissue (dWAT), a prominent source of adiponectin (APN). We…
Abstract Number: 820 • 2016 ACR/ARHP Annual Meeting
EZH2 Modulates Angiogenesis and Fibrosis in Scleroderma
Pei-Suen Tsou, Patrick Coit, Dinesh Khanna and Amr H Sawalha, Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Scleroderma (SSc) is a complex disease that involves activation of the immune system, vascular complications, and tissue fibrosis. Although the pathogenesis of this disease…
Abstract Number: 821 • 2016 ACR/ARHP Annual Meeting
IL-31 Is an Inflammatory Pro-Fibrotic Factor Elevated in a Subset of Scleroderma Patients with Severe Pruritus
Bahja Ahmed Abdi¹, Sara Zafar², Zeinab Taki³, Nikita Arumalla⁴, Shiwen Xu⁵, Christopher Denton⁴, David Abraham⁴ and Richard J. Stratton⁶, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Centre of Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ³Department of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ⁴Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁵Division of Medicine, Centre for Rheumatology and Connective tissue disease, University College London, London, United Kingdom, ⁶Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune rheumatic disease associated with fibroblast activation in the skin and visceral organs. In SSc, refractory pruritus is a…
Abstract Number: 822 • 2016 ACR/ARHP Annual Meeting
Pulmonary Fibrosis in Mixed Connective Tissue Disease – Results from an Unselected Longitudinal Cohort
Silje Reiseter¹, Trond Mogens Aalokken², Ragnar Gunnarsson³, May Brit Lund⁴, Johanna Haydon⁵ and Øyvind Molberg^6,7, ¹Rheumatology, University of Oslo, Rikshospitalet, Oslo, Norway, ²Radiology, Oslo University Hospital, Oslo, Norway, ³Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁴Respiratory Medicine, Oslo University Hospital, Oslo, Norway, ⁵Rheumatology, Vestre Viken Hospital, Drammen, Norway, ⁶Institute of Clinical Medicine, University of Oslo, Oslo, Norway, ⁷Rheumatology, Oslo University Hospital, Oslo, Norway
Background/Purpose: Mixed Connective Tissue Disease (MCTD) is a chronic, immune-mediated disorder defined by the combined presence of serum anti-ribonucleoprotein (RNP) antibodies and selected clinical features…
Abstract Number: 823 • 2016 ACR/ARHP Annual Meeting
A Phase 2 Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness in Subjects with Systemic Sclerosis with Interstitial Lung Disease
Vivien Hsu¹, Christopher P.Denton², Robyn T. Domsic³, Daniel E. Furst⁴, Maureen Rischmueller⁵, Marina Stanislav⁶, Virginia D. Steen⁷, Douglas Hough⁸, Shimon Korish⁹, Alyse Cooper¹⁰, Peter H. Schafer¹¹ and Suktae Choi¹², ¹Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, ²Centre of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ³Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵University of Adelaide, Adelaide, Australia, ⁶Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russia, ⁷Rheumatology, Georgetown University Medical Center, Washington, DC, ⁸Clinical Research, Celgene Corporation, Warren, NJ, ⁹33 Technology Drive, Celgene Corporation, Warren, NJ, ¹⁰Immunology & Inflammation, Clinical Research, Celgene Corporation, Summit, NJ, ¹¹Department of Translational Development, Celgene Corporation, Summit, NJ, ¹²Biostatistics, Celgene Corporation, Summit, NJ
Background/Purpose: Pomalidomide (POM) is an IMiD compound, structurally similar to thalidomide. POM binds to cereblon and facilitates Ikaros and Aiolos degradation, resulting in immunomodulation of…
Abstract Number: 824 • 2016 ACR/ARHP Annual Meeting
Mycophenolate Versus Placebo for the Treatment of Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth R. Volkmann¹, Donald P. Tashkin², Ning Li³, Michael Roth⁴, Dinesh Khanna⁵, Anna-Maria Hoffmann-Vold⁶, Philip J. Clements⁴, Daniel E. Furst¹, Robert Elashoff⁷ and Scleroderma Lung Study II Group, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ³UCLA, Los Angeles, CA, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Michigan, Ann Arbor, MI, ⁶Oslo University Hospital, Oslo, Norway, ⁷Biomathematics, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Compared with placebo, treatment with cyclophosphamide (CYC) improved lung function and dyspnea in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).1 While treatment with…
Abstract Number: 825 • 2016 ACR/ARHP Annual Meeting
KL-6 and Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis Related Interstitial Lung Disease
Gloria Salazar¹, Masataka Kuwana², Minghua Wu¹, Jun Ying¹, Julio Charles³, Maureen D Mayes¹ and Shervin Assassi¹, ¹Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Internal Medicine-Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: Pneumoproteins are attractive biomarker candidates in systemic sclerosis (SSc) related interstitial lung disease (ILD) because they are easily obtainable and lung-specific. KL-6 and CCL-18…
Abstract Number: 826 • 2016 ACR/ARHP Annual Meeting
Exercise Echocardiography Predicts Future Development of Pulmonary Hypertension in a High-Risk Cohort of Scleroderma Patients
Kaitlin A. Quinn¹, Tunay Kuru², Stephanie Wappel³ and Virginia D. Steen¹, ¹Rheumatology, Georgetown University Medical Center, Washington, DC, ²Pulmonary, Georgetown University Medical Center, Washington, DC, ³Georgetown University Medical Center, Washington, DC
Background/Purpose: Pulmonary hypertension (PH) is the leading cause of scleroderma related deaths and is often detected late in the disease course. Early identification of patients…
Abstract Number: 827 • 2016 ACR/ARHP Annual Meeting
Severe Gastrointestinal Disease in Early Systemic Sclerosis Is Associated with an Increased Risk of Mortality
Nicolas Richard¹, Marie Hudson², Mianbo Wang³, Murray Baron⁴, Genevieve Gyger¹ and Canadian Scleroderma Research Group, ¹McGill University, Jewish General Hospital, Montreal, QC, Canada, ²Medicine/Rheumatology, Jewish General Hospital, Lady Davis Research Institute, Montreal, QC, Canada, ³Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁴Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Studies of severe gastrointestinal (GI) disease in systemic sclerosis (SSc) are limited by small, selected samples composed largely of subjects with prevalent disease. We…
Abstract Number: 828 • 2016 ACR/ARHP Annual Meeting
Survival and Health-Related Quality of Life in Incident Systemic Sclerosis Related Pulmonary Arterial Hypertension: A Multicentre Australian Cohort Study
Kathleen Morrisroe¹, Molla Huq², Wendy Stevens³, Candice Rabusa⁴, Joanne Sahhar⁵, Gene Ngian⁶, Susanna Proudman^7,8, Mandana Nikpour⁹ and Australian Scleroderma Interest Group, ¹Rheumatology, St Vincent's Hospital, Melbourne, Melbourne, Australia, ²Department of Medicine (Rheumatology), Melbourne University, Melbourne, Australia, ³Department of Rheumatology, St. Vincent’s Hospital Melbourne, Melbourne, Australia, ⁴Rheumatology, St. Vincent’s Hospital, Melbourne, Australia, ⁵Department of Rheumatology, Monash Medical Centre, Melbourne, Australia, ⁶Department of Medicine (RMH/WH), The University of Melbourne, Melbourne, Australia, ⁷Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁸Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁹Melbourne University, Melbourne, Australia
Background/Purpose: Pulmonary arterial hypertension (PAH) is the leading cause of systemic sclerosis (SSc) related mortality. We sought to determine survival, predictors of mortality, and health…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].